Cargando…
Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687287/ https://www.ncbi.nlm.nih.gov/pubmed/23695816 http://dx.doi.org/10.2337/dc13-0895 |
| _version_ | 1782273897977085952 |
|---|---|
| author | Cefalu, William T. Rosenstock, Julio Henry, Robert R. Riddle, Matthew |
| author_facet | Cefalu, William T. Rosenstock, Julio Henry, Robert R. Riddle, Matthew |
| author_sort | Cefalu, William T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3687287 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-36872872014-07-01 Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance Cefalu, William T. Rosenstock, Julio Henry, Robert R. Riddle, Matthew Diabetes Care Editorial American Diabetes Association 2013-07 2013-06-12 /pmc/articles/PMC3687287/ /pubmed/23695816 http://dx.doi.org/10.2337/dc13-0895 Text en © 2013 by the American Diabetes Association. https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ (https://creativecommons.org/licenses/by-nc-nd/3.0/) for details. |
| spellingShingle | Editorial Cefalu, William T. Rosenstock, Julio Henry, Robert R. Riddle, Matthew Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance |
| title | Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance |
| title_full | Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance |
| title_fullStr | Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance |
| title_full_unstemmed | Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance |
| title_short | Signals and Noise in Drug Safety Analyses: The incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance |
| title_sort | signals and noise in drug safety analyses: the incretin therapy debate provides the rationale for revamping epidemiologic pharmacovigilance |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687287/ https://www.ncbi.nlm.nih.gov/pubmed/23695816 http://dx.doi.org/10.2337/dc13-0895 |
| work_keys_str_mv | AT cefaluwilliamt signalsandnoiseindrugsafetyanalysestheincretintherapydebateprovidestherationaleforrevampingepidemiologicpharmacovigilance AT rosenstockjulio signalsandnoiseindrugsafetyanalysestheincretintherapydebateprovidestherationaleforrevampingepidemiologicpharmacovigilance AT henryrobertr signalsandnoiseindrugsafetyanalysestheincretintherapydebateprovidestherationaleforrevampingepidemiologicpharmacovigilance AT riddlematthew signalsandnoiseindrugsafetyanalysestheincretintherapydebateprovidestherationaleforrevampingepidemiologicpharmacovigilance |